Valdez-Acosta, S.; Zubiaur, P.; Casado, M.A.; Novalbos, J.; Casajús, A.; Campodónico, D.; Oyagüez, I.; Abad-Santos, F.
Preemptive TPMT Genotyping and Adherence to Genotype-Based Therapeutic Recommendations Reduces the Healthcare Cost in Patients Receiving Azathioprine or 6-Mercaptopurine for Autoimmune Diseases. J. Pers. Med. 2023, 13, 1208.
https://doi.org/10.3390/jpm13081208
AMA Style
Valdez-Acosta S, Zubiaur P, Casado MA, Novalbos J, Casajús A, Campodónico D, Oyagüez I, Abad-Santos F.
Preemptive TPMT Genotyping and Adherence to Genotype-Based Therapeutic Recommendations Reduces the Healthcare Cost in Patients Receiving Azathioprine or 6-Mercaptopurine for Autoimmune Diseases. Journal of Personalized Medicine. 2023; 13(8):1208.
https://doi.org/10.3390/jpm13081208
Chicago/Turabian Style
Valdez-Acosta, SarahÃ, Pablo Zubiaur, Miguel Angel Casado, Jesús Novalbos, Ana Casajús, Diana Campodónico, Itziar Oyagüez, and Francisco Abad-Santos.
2023. "Preemptive TPMT Genotyping and Adherence to Genotype-Based Therapeutic Recommendations Reduces the Healthcare Cost in Patients Receiving Azathioprine or 6-Mercaptopurine for Autoimmune Diseases" Journal of Personalized Medicine 13, no. 8: 1208.
https://doi.org/10.3390/jpm13081208
APA Style
Valdez-Acosta, S., Zubiaur, P., Casado, M. A., Novalbos, J., Casajús, A., Campodónico, D., Oyagüez, I., & Abad-Santos, F.
(2023). Preemptive TPMT Genotyping and Adherence to Genotype-Based Therapeutic Recommendations Reduces the Healthcare Cost in Patients Receiving Azathioprine or 6-Mercaptopurine for Autoimmune Diseases. Journal of Personalized Medicine, 13(8), 1208.
https://doi.org/10.3390/jpm13081208